evogliptin + glimepiride

Evogliptin + glimepiride is a fixed-dose combination of two oral antidiabetic agents used in the management of type 2 diabetes mellitus. Evogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release. Glimepiride is a second-generation sulfonylurea that stimulates pancreatic beta cells to secrete insulin by blocking ATP-sensitive potassium channels. The combination provides an additive glucose-lowering effect without significant pharmacokinetic interactions between the two drugs[1][3][5]. This therapy is indicated for patients with type 2 diabetes who require improved glycemic control. Developers: Dong-A ST (for evogliptin), Sanofi (for glimepiride)